mRNA-1345の市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

mRNA-1345ワクチンは、メッセンジャーRNA（mRNA）ワクチンです。このmRNAはすべて実験室で作られ、体内でタンパク質の小片を作るよう指示します。ModernaのmRNA-1345 RSVワクチン候補はプレフュージョンF糖タンパク質をコードしており、優れた中和抗体反応を誘発します。

この場合、ワクチン候補にはRSV糖タンパク質FのmRNAコードが含まれており、このタンパク質はRSV感染を引き起こしませんが、ウイルスに遭遇した場合に身体の免疫システムが認識し、自身を守るのを助けます。したがって、この治験用ワクチンを接種してもRSVに感染することはありません。mRNA-1345RSVワクチン候補は、若年者と高齢者（65歳以上）の呼吸器疾患の主因であるRSVによる疾病を予防します。現在、この薬剤は高齢者を対象としたフェーズ3試験中です。mRNA-1345はまた、小児を対象としたフェーズI試験も進行中であり、RSVは小児においても大きな負担となっています。

RSVプログラムは、当社の呼吸器合胞体ウイルス（RSV）ワクチン候補であるmRNA-1345の60歳以上の成人を対象とした主な臨床試験のフェーズ3部分の開始を承認しました。DSMBの承認は、予備的なフェーズIIデータの独立したレビューの結果得られたものであり、その結果、このワクチンは選択された用量で高齢者において許容可能な安全性プロファイルを有することが示されました。この試験はConquerRSVとして知られています。

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）におけるRSV向けmRNA-1345について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 RSVにおけるmRNA-1345の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 mRNA-1345市場の評価

• RSVにおけるmRNA-1345の市場見通し
• 主要7市場の分析
  • 主要7市場のRSV向けmRNA-1345の市場規模
• 市場の分析：国別
  • 米国のRSV向けmRNA-1345の市場規模
  • ドイツのRSV向けmRNA-1345の市場規模
  • 英国のRSV向けmRNA-1345の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: mRNA-1345, Clinical Trial Description, 2023
• Table 2: mRNA-1345, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: mRNA-1345 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: mRNA-1345 Market Size in the US, in USD million (2019-2032)
• Table 7: mRNA-1345 Market Size in Germany, in USD million (2019-2032)
• Table 8: mRNA-1345 Market Size in France, in USD million (2019-2032)
• Table 9: mRNA-1345 Market Size in Italy, in USD million (2019-2032)
• Table 10: mRNA-1345 Market Size in Spain, in USD million (2019-2032)
• Table 11: mRNA-1345 Market Size in the UK, in USD million (2019-2032)
• Table 12: mRNA-1345 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: mRNA-1345 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: mRNA-1345 Market Size in the United States, USD million (2019-2032)
• Figure 3: mRNA-1345 Market Size in Germany, USD million (2019-2032)
• Figure 4: mRNA-1345 Market Size in France, USD million (2019-2032)
• Figure 5: mRNA-1345 Market Size in Italy, USD million (2019-2032)
• Figure 6: mRNA-1345 Market Size in Spain, USD million (2019-2032)
• Figure 7: mRNA-1345 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: mRNA-1345 Market Size in Japan, USD million (2019-2032)

"mRNA-1345 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the mRNA-1345 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mRNA-1345 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mRNA-1345 market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary:

The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna's mRNA-1345 RSV vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response.

In this case, the vaccine candidate contains the mRNA code for the RSV glycoprotein F, which does not cause RSV infection but helps the body's immune system recognize and protect itself if it encounters the virus. Therefore, one cannot become infected with RSV by receiving the investigational vaccine. The mRNA-1345 RSV vaccine candidate prevents illness from RSV, a leading cause of respiratory illness in young and older adults (65+). Currently, the drug is in Phase III for older adults. mRNA-1345 is also ongoing in a Phase I trial in pediatric populations; RSV is also a large burden in the pediatric population.

RSV program has endorsed the start of the Phase III portion of the pivotal clinical study of mRNA-1345, the Company's Respiratory Syncytial Virus (RSV) vaccine candidate, in adults 60 years and older. The DSMB's endorsement comes after independent review of preliminary Phase II data, which suggest that the vaccine has an acceptable safety profile in older adults at the selected dose. This study is known as ConquerRSV.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the mRNA-1345 description, mechanism of action, dosage and administration, research and development activities in Respiratory syncytial virus (RSV).
• Elaborated details on mRNA-1345 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the mRNA-1345 research and development activities in RSV across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around mRNA-1345.
• The report contains forecasted sales of mRNA-1345 for RSV till 2032.
• Comprehensive coverage of the late-stage emerging therapies for RSV.
• The report also features the SWOT analysis with analyst views for mRNA-1345 in RSV.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

mRNA-1345 Analytical Perspective by DelveInsight

• In-depth mRNA-1345 Market Assessment

This report provides a detailed market assessment of mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• mRNA-1345 Clinical Assessment

The report provides the clinical trials information of mRNA-1345 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence mRNA-1345 dominance.
• Other emerging products for RSV are expected to give tough market competition to mRNA-1345 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of mRNA-1345 in RSV.
• Our in-depth analysis of the forecasted sales data of mRNA-1345 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the mRNA-1345 in RSV.

Key Questions:

• What is the product type, route of administration and mechanism of action of mRNA-1345?
• What is the clinical trial status of the study related to mRNA-1345 in Respiratory syncytial virus (RSV) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the mRNA-1345 development?
• What are the key designations that have been granted to mRNA-1345 for RSV?
• What is the forecasted market scenario of mRNA-1345 for RSV?
• What are the forecasted sales of mRNA-1345 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to mRNA-1345 for RSV?
• Which are the late-stage emerging therapies under development for the treatment of RSV?

Table of Contents

1. Report Introduction

2. mRNA-1345 Overview in RSV

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. mRNA-1345 Market Assessment

• 5.1. Market Outlook of mRNA-1345 in RSV
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of mRNA-1345 in the 7MM for RSV
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of mRNA-1345 in the United States for RSV
  • 5.3.2. Market Size of mRNA-1345 in Germany for RSV
  • 5.3.3. Market Size of mRNA-1345 in France for RSV
  • 5.3.4. Market Size of mRNA-1345 in Italy for RSV
  • 5.3.5. Market Size of mRNA-1345 in Spain for RSV
  • 5.3.6. Market Size of mRNA-1345 in the United Kingdom for RSV
  • 5.3.7. Market Size of mRNA-1345 in Japan for RSV

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options